Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis

Clinical Therapeutics

Volumn 21, Issue 9, 1999, Pages 1497-1513

  Goldenberg, Marvin M ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b Managed Health Care Associates Inc   (United States)

Author keywords

Celecoxib; COX 2 inhibitors; NSAID; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SULFONAMIDE;

ANIMAL MODEL; AREA UNDER THE CURVE; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; VERTIGO;

EID: 0032818121     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80005-3     Document Type: Article

References (56)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231:232-235.
2. Smith WL, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature. 1971;231:235-237.
3. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974;26:33-67.
4. Cronstein BN, Weissmann G. Target for anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1995;35:449-462.
5. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol. 1993;88:1318-1323.
6. Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med. 1996;156:1623-1628.
7. Fries JF, Miller SR, Williams CA, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology. 1989;96:647-655.
8. Marnett L. Aspirin and the potential role for prostaglandins in colon cancer. Cancer Res. 1992;52:5575-5589.
9. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: Structure and catalysis. Biochim Biophys Acta. 1991;1083:1-17.
10. 2 synthase-1. Nature. 1994;367:243-249.
11. Roth GI, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA. 1975;72:3073-3076.
12. Eberhart CE, Du Bois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109:285-301.
13. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phase. Proc Natl Acad Sci USA. 1989;86:1657-1661.
14. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.
15. Masferrer JL, Seibert K, Zweifel BS, et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA. 1992;89:3917-3921.
16. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692-2696.
17. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS 10, a phorbol ester tumor promoter - inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-12872.
18. O'Banion MK, Sadowski HB, Winn V, et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991;266:23261-23267.
19. Smith WL, De Witt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. Immunology. 1996;62:167-215.
20. Masferrer J, Zweifel B, Manning PT. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994;91:3228-3232.
21. Appelby SB, Ristimaki A, Neilson K, et al. Structure of human cyclooxygenase-2 gene. Biochem J. 1994;302:723-727.
22. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994;221:889-897.
23. Ristimaki A, Garfinkel S, Wessendorf J, et al. Induction of cyclooxygenase-2 by interleukin-1 alpha. J Biol Chem. 1994;269:11769-11775.
24. De Witt DL, Meade E. Serum and glucocorticoid regulation of gene transcription and expression of prostaglandin H synthase-1 and prostaglandin H synthase-2 isoenzymes. Arch Biochem Biophys. 1993;306:94-102.
25. Hoff T, De Witt DL, Kaever V, et al. Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett. 1993;320:38-42.
26. Siebert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase (COX)-2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013-12017.
27. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA. 1994;91:2046-2050.
28. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994;93:1095-1101.
29. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem. 1992;267:25934-25938.
30. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993;268:9049-9054.
31. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997;24(Suppl 49):15-19.
32. Sano H, Hla T, Maier JAM, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97-108.
33. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994;45:245-254.
34. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J. 1995;305:479-484.
35. Laneuville O, Breuer DK, De Witt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases 1 and 2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
36. Vane JR. Mechanism of action of NSAIDs. Br J Rheumatol. 1996;35(Suppl 1):1-3.
37. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-[H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.
38. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644-648.
39. Hawkey CJ. COX-2 inhibitors. Lancer. 1999;353:307-314.
40. Anderson GD, Hauser SD, McGarity KL, et al. Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996;97:2672-2679.
41. Celebrex [package insert]. Skokie, III: G.D. Searle & Co.; 1999.
42. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277.
43. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum. 1996;39(Suppl 9):S226. Abstract.
44. Simon LS, Lanza F, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
45. The Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum. 1965;8:302-334.
46. Zhao SZ, Hind TH, Hubbard RC, et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. Arthritis Rheum. 1997;40(Suppl 9):S88. Abstract.
47. Hubbard RC, Koepp R, Shawn S, et al. Pilot study of efficacy of SC-58635, a COX-2-selective inhibitor, in rheumatoid arthritis. Arthritis Rheum. 1997;40(Suppl 9):S51. Abstract.
48. Geis GS, Stead H, Morant S, et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(Suppl 9):S316. Abstract.
49. Karim A, Tolbert D, Piergies A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. Arthritis Rheum. 1998;41(Suppl 9):S315. Abstract.
50. Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med. 1996;44:293. Abstract.
51. Lanza F, Callison DA, Hubbard RC, et al. A pilot endoscopic study of the gastro-duodenal effects of SC-58635, a Cox-2-selective inhibitor. Arthritis Rheum. 1997;40(Suppl 9):S93. Abstract.
52. Mengle-Gaw LJ, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor. Arthritis Rheum. 1997;40(Suppl 9):S88. Abstract.
53. Searle/Pfizer Celebrex label should include GI superiority to NSAIDs-Cmte. FDC Reports. 1998;60:3-4.
54. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs-differences and similarities. N Engl J Med. 1991;324:1716-1725.
55. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol. 1991;31:588-598.
56. Needleman P, Isakson PC. Selective inhibition of cyclooxygenase 2. Sci Med. 1998;1:35-36.